Precision Medicine at Geisinger
Precision Medicine at Geisinger
批准号:
9355320
负责人:
David H. Ledbetter
金额:
$42.91万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-27 至 2017-06-16
关键词:
AdoptedAreaBackBehavioralBloodClinicalClinical DataClinical InformaticsCollectionCommunity HealthDataData ReportingDatabasesDiseaseElementsEmergency CareEnrollmentEnvironmental ExposureFamilyFutureGenerationsGenomic medicineGenomicsGoalsHealthHealth PersonnelHealth systemHealthcareInformaticsInformed ConsentInpatientsLocationLongitudinal StudiesMedical centerNew JerseyPMI cohortParticipantPatientsPennsylvaniaPersonsPhysical ExaminationPopulationPrecision Medicine InitiativeRecruitment ActivityResearchResearch InfrastructureRuralSalivaStable PopulationsSurveysSystemTelephoneTrustUrineclinical data warehousedata sharingdesignexperiencehealth care deliveryhealth disparityimplementation researchmedical specialtiesmobile applicationmobile computingmonitoring devicepatient populationprecision medicineprogramspsychosocialresponserural areasensorsocioeconomic disparitysocioeconomicssound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Geisinger Health System (GHS) is fully prepared and “shovel-ready” to participate as a Regional Medical Center Healthcare Provider Enrollment Center for the Precision Medicine Initiative (PMI). GHS is an integrated healthcare delivery system serving regions in New Jersey and Pennsylvania with a total population of >3M, of which a significant portion resides in small towns and rural areas. This area is densely rural, with significant socioeconomic and health disparities. The population is notable for its very low rate of relocation in/out of the area and the large number of multi-generation families receiving their healthcare in this single integrated system. This stability provides tremendous opportunity for genomics research and implementation – along with a century-old tradition of trust between the system and its patients. In brief, GHS patients represent a generally rural, underserved and lower socio-economic population, an important component of PMI diversity. A pioneer in utilization of EHRs and clinical informatics, GHS adopted Epic in 1996 and now has two decades of longitudinal clinical data on its patients. In addition to Epic, we have a well-established comprehensive enterprise clinical data warehouse, extensive experience extracting clinical information from the EHR and data warehouse and a patient population already partnering with us in precision medicine research. That partnership dates back to 2006 when after extensive engagement with patients and other stakeholders, GHS created a system-wide program for genomics research, the MyCode® Community Health Initiative. MyCode® is designed to recruit participants, regardless of health or disease status, from the health system and now provides an effective framework for precision medicine research and implementation of genomic medicine through a return of results program. To date, MyCode® has enrolled ≥113,000 participants, all of whom have extensive longitudinal EHR data (average of ~13 years) covering primary, specialty, inpatient, and emergency care, as well as geocoding for integration with public databases including environmental data. MyCode® closely mirrors the proposed design of the national PMI cohort including participant engagement; informed consent for broad research use; data sharing and return of results; longitudinal EHR data; collection of additional participant data via diverse mechanisms and engagement strategies (online patient portal, mobile technologies, mail and telephone surveys, and in-person interactions). MyCode® demonstrates GHS’s capabilities in precision medicine. We propose to leverage our MyCode® experience and infrastructure with the additional elements defined by the PMI Steering Committee to create a separate PMI recruitment initiative at GHS. The combination of a large stable population and a long standing trusting relationship makes Geisinger the perfect place for longitudinal studies like the PMI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Leveraging rare genetic etiologies to advance knowledge and treatment of neuropsychiatric disorders
-
批准号:9761734
-
项目类别:
-
资助金额:$173.83万
-
财政年份:2019
-
负责人:David H. Ledbetter
-
依托单位:
Leveraging rare genetic etiologies to advance knowledge and treatment of neuropsychiatric disorders
-
批准号:10597665
-
项目类别:
-
资助金额:$182.67万
-
财政年份:2019
-
负责人:David H. Ledbetter
-
依托单位:
Leveraging rare genetic etiologies to advance knowledge and treatment of neuropsychiatric disorders
-
批准号:10400634
-
项目类别:
-
资助金额:$184.51万
-
财政年份:2019
-
负责人:David H. Ledbetter
-
依托单位:
A Unified Clinical Genomics Database
-
批准号:8503747
-
项目类别:
-
资助金额:$296.19万
-
财政年份:2013
-
负责人:David H. Ledbetter
-
依托单位:
A Unified Clinical Genomics Database
-
批准号:8914452
-
项目类别:
-
资助金额:$268.12万
-
财政年份:2013
-
负责人:David H. Ledbetter
-
依托单位:
Clinical Genome Resource
-
批准号:9755466
-
项目类别:
-
资助金额:$425.64万
-
财政年份:2013
-
负责人:David H. Ledbetter
-
依托单位:
A Unified Clinical Genomics Database
-
批准号:8739539
-
项目类别:
-
资助金额:$269.5万
-
财政年份:2013
-
负责人:David H. Ledbetter
-
依托单位:
Clinical Genome Resource
-
批准号:9359632
-
项目类别:
-
资助金额:$306.17万
-
财政年份:2013
-
负责人:David H. Ledbetter
-
依托单位:
CNV Atlas of Human Development
-
批准号:7944065
-
项目类别:
-
资助金额:$169.65万
-
财政年份:2009
-
负责人:David H. Ledbetter
-
依托单位:
CNV Atlas of Human Development
-
批准号:7859755
-
项目类别:
-
资助金额:$172.75万
-
财政年份:2009
-
负责人:David H. Ledbetter
-
依托单位:
GENE DOSAGE IMBALANCE IN NEURODEVELOPMENTAL DISORDERS
-
批准号:8468208
-
项目类别:
-
资助金额:$66.24万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
GENE DOSAGE IMBALANCE IN NEURODEVELOPMENTAL DISORDERS
-
批准号:7889793
-
项目类别:
-
资助金额:$69.62万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
Gene Dosage Imbalance in Neurodevelopmental Disorders
-
批准号:10375879
-
项目类别:
-
资助金额:$81.04万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
GENE DOSAGE IMBALANCE IN NEURODEVELOPMENTAL DISORDERS
-
批准号:8109948
-
项目类别:
-
资助金额:$68.98万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
GENE DOSAGE IMBALANCE IN NEURODEVELOPMENTAL DISORDERS
-
批准号:8270114
-
项目类别:
-
资助金额:$69.0万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
GENE DOSAGE IMBALANCE IN NEURODEVELOPMENTAL DISORDERS
-
批准号:8546604
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
Gene Dosage Imbalance in Neurodevelopmental Disorders
-
批准号:9275015
-
项目类别:
-
资助金额:$78.52万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
Gene Dosage Imbalance in Neurodevelopmental Disorders
-
批准号:6915834
-
项目类别:
-
资助金额:$40.51万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
Gene Dosage Imbalance in Neurodevelopmental Disorders
-
批准号:7580882
-
项目类别:
-
资助金额:$41.98万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
Gene Dosage Imbalance in Neurodevelopmental Disorders
-
批准号:9908185
-
项目类别:
-
资助金额:$75.14万
-
财政年份:2005
-
负责人:David H. Ledbetter
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: